AstraZeneca posts Q2 pipeline setbacks: mixed ADC data in gastric cancer, an Ultomiris TMA trial miss and an Imfinzi liver cancer failure.
July 27, 2026 07:03 AM EDT
R&DPharma
AstraZeneca’s pipeline struggles continue as it reports disappointing data in cancer, rare disease
Ayisha Sharma
News Reporter
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel…
AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern…
AstraZeneca on Monday reported data from a new combination study showing a combination of targeted and immunotherapies can…
AstraZeneca CEO Pascal Soriot says AI could boost late-stage trial success and speed FDA filings, following Wainua's surprise…
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
